[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"local-anaesthetic-systemic-toxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:local-anaesthetic-systemic-toxicity":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100639984","plasma-kinetics-of-levobupivacaine-after-transversus-abdominis-plane-tap-block-in-abdominal-surgery-100639984",false,"NCT07581275","Plasma Kinetics of Levobupivacaine After Transversus Abdominis Plane (TAP) Block in Abdominal Surgery","Plasma Kinetics of Levobupivacaine After Transversus Abdominis Plane (TAP) Block in Abdominal Surgery: A Prospective Study and Definition of a Safety Window for Intravenous Lidocaine Administration","LEVO-TAP-PK","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled elective abdominal surgery under general anesthesia\n* Planned ultrasound-guided TAP block as part of standard perioperative analgesic care\n* Able to understand and speak French sufficiently to understand the study information and consent form\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\n* Known allergy or hypersensitivity to amide local anesthetics\n* Severe hepatic impairment\n* Renal impairment (estimated glomerular filtration rate \\\u003C50 mL\u002Fmin\u002F1.73 m²)\n* Contraindication to repeated blood sampling or inability to complete the sampling schedule\n* Participation in another clinical study that could affect absorption, distribution, metabolism, or elimination of local anesthetics\n* Pregnancy\n* Emergency surgery or life-threatening urgent condition\n* Immediate postoperative instability requiring intensive care transfer (e.g., hemodynamic instability)\n* Inability to understand French sufficiently for study information and consent\n* Persons requiring special legal protection for consent (e.g., minors, guardianship, incapacity to consent)","ALL","18 Years","75 Years",{"count":21,"type":22},26,"ESTIMATED","OBSERVATIONAL","This prospective single-center observational pharmacokinetic study will evaluate plasma levobupivacaine concentrations after ultrasound-guided transversus abdominis plane (TAP) block in adult patients undergoing elective abdominal surgery under general anesthesia at CHU Liège. Participants receiving TAP block as part of standard clinical care (levobupivacaine 0.375%, total volume 40 mL, maximum dose 150 mg) will undergo serial blood sampling at 3, 7, 15, 30, 60, 120, and 180 minutes after block completion. Plasma levobupivacaine concentrations will be measured using validated LC-MS\u002FMS methods. The primary objectives are to estimate maximum plasma concentration (Cmax) and time to maximum concentration (Tmax). Secondary objectives include characterization of the concentration-time profile, AUC0-180, interindividual variability, and exploratory associations with clinical factors (age, sex, BMI, type of surgery). The study also aims to inform a pragmatic safety window for subsequent intravenous lidocaine infusion used in multimodal analgesia protocols. Approximately 26 participants will be enrolled. No modification of routine anesthesia or analgesic care is required apart from study-related blood sampling.",[26,27,28,29,30],"Abdominal Surgery Patients","Transversus Abdominis Plane (TAP) Block","Pharmacokinetic Analysis","Levobupivacaine","Local Anaesthetic Systemic Toxicity","NOT_YET_RECRUITING","2026-05-06",{"date":34,"type":35},"2026-05-12","ACTUAL",{"date":37,"type":22},"2026-07-01",{"date":39,"type":22},"2026-12-15",{"name":41,"class":42},"University of Liege","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100624828","phase-3-intravenous-lidocaine-plus-port-site-ropivacaine-for-recovery-after-laparoscopic-surgery-100624828","NCT07414706","Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery","Evaluation of Postoperative Recovery When Combining Intravenous Lidocaine With Ropivacaine Infiltrations in Colorectal Laparoscopic Surgery","LivQor","Inclusion Criteria:\n\n* Patient undergoing scheduled colorectal cancer surgery via laparoscopy.\n* Patient aged 18 years or older.\n* Informed consent obtained and signed.\n* Affiliation to a social security system.\n\nExclusion Criteria:\n\n* Allergy or contraindication to lidocaine or ropivacaine.\n* Allergy or contraindication to paracetamol, nefopam ketamine, propofol, dexamethasone, sufentanil, Celebrex or parecoxib, morphine derivatives, and colorectal surgery by laparotomy\n* Colorectal surgery with a non-cancerous indication.\n* Chronic preoperative pain (defined as persistent pain for more than 3 months).\n* Preoperative use of opioids or opioid derivatives.\n* Patients with psychiatric disorders.\n* Patients for whom self-assessment of pain using a self-reported scale cannot be performed (non-communicative, non-French speaking, etc.).\n* Pregnant or breastfeeding women.\n* Patients under guardianship, curatorship, or legal protection.",{"count":52,"type":22},182,"INTERVENTIONAL",[55],"PHASE3","This randomized controlled trial evaluates whether perioperative intravenous lidocaine infusion, combined with port-site ropivacaine infiltration, improves postoperative recovery after laparoscopic abdominal surgery. Participants will be assigned 1:1 to receive either intravenous lidocaine during surgery plus ropivacaine infiltration at surgical closure, or ropivacaine infiltration alone. The primary endpoint is postoperative quality of recovery measured by the QoR-15 questionnaire. Secondary endpoints include postoperative pain and opioid consumption, as well as plasma lidocaine and ropivacaine concentrations to assess systemic exposure and safety.",[58,59,60,30],"Intravenous Lidocaine","Laparoscopic Surgery","Post Operative Recovery",[62,63,64,65],"Intravenous lidocaine","laparoscopic surgery","post operative recovery","local anaesthetic systemic toxicity","2026-02-12",{"date":68,"type":35},"2026-02-17",{"date":70,"type":22},"2026-03",{"date":72,"type":22},"2028-09",{"name":74,"class":42},"Centre Hospitalier Universitaire, Amiens",1]